CHF Solutions' Aquadex FlexFlow System
November 1, 2018 — Daxor Corp. has entered an agreement with CHF Solutions to explore clinical synergies between Daxor’s BVA-100 Blood Volume Analyzer and CHF Solutions’ Aquadex FlexFlow System for heart failure patients. More specifically, the two companies will assess the benefit of combining Daxor’s fluid volume diagnostic with Aquadex FlexFlow therapy for the management of the fluid-overloaded patient.
The collaboration will initiate with an evaluation of the benefits of blood volume measurement in helping to determine ultrafiltration management with CHFS’s Aquadex FlexFlow system in a pilot study. Recently published outcomes of 245 heart failure admissions showed a decrease in heart failure mortality of 86 percent and 30-day readmissions of 56 percent when the BVA-100 diagnostic was used to guide treatment. A subset of those data included treatment using the Aquadex FlexFlow system to reduce fluid overload. The pilot study is intended to provide additional insight on the potential benefit of using the devices in tandem to enhance clinical outcomes. Specific points of inquiry will include how the two systems can assist with informing clinicians on fluid volume status including patient selection, when to start ultrafiltration therapy, and how to manage therapy to achieve positive clinical results for patients.
For more information: www.daxor.com, www.chf-solutions.com
October 28, 2025 
